T1	Intervention 0 17	Tissue microarray
T2	Intervention 192 238	standard combination chemotherapy (CHOP, n=48)
T3	Intervention 269 285	rituximab (n=45)
T4	Intervention 309 350	investigational immunohistochemical (IHC)
T5	Intervention 357 380	tissue microarray (TMA)
T6	Intervention 385 666	contrasted to the approximately corresponding categories as defined either by Hans and associates using a three marker panel into germinal or non-germinal centre subtypes or by Choi and colleagues with two additional antibodies into germinal centre (GCB) or activated B-cells (ABC)
T7	Intervention 825 834	rituximab
T8	Intervention 1013 1019	R-CHOP
T9	Intervention 1074 1090	subtype analysis
T10	Intervention 1153 1168	cytotoxic drugs
T11	Intervention 1462 1492	anti CD 20 monoclonal antibody
T12	Intervention 1528 1566	chemotherapy or immunotherapy antibody
T13	Intervention 1753 1778	immunohistochemical (IHC)
T14	Intervention 1881 1886	BCL2,
T15	Intervention 1931 2006	treatment modality (chemotherapy with or without the addition of rituximab)
T16	Intervention 2121 2140	BCL2 positive group
T17	Intervention 2184 2217	rituximab containing chemotherapy
T18	Intervention 2431 2450	LMO2 positive group
T19	Intervention 2489 2517	rituximab containing regimen
T20	Intervention 2534 2559	IHC based TMA methodology
T21	Intervention 2629 2660	gene expression profiling (GEP)
T22	Intervention 2799 2804	DLBCL
T23	Intervention 2975 2987	chemotherapy
T24	Intervention 3055 3064	rituximab
T25	Intervention 3187 3196	rituximab
T26	Intervention 3221 3233	chemotherapy
T27	Intervention 3492 3510	immunochemotherapy
